Search Results - "Patterson, L. H."

Polysialyltransferase: a new target in metastatic cancer by Falconer, R A, Errington, R J, Shnyder, S D, Smith, P J, Patterson, L H

“…Polysialic acid (polySia) is a carbohydrate polymer critical for neuronal cell migration and axon pathfinding in embryonic development. Besides brain regions…”
Get more information

Characterization of Changes in the Proteome in Different Regions of 3D Multicell Tumor Spheroids by McMahon, K. M, Volpato, M, Chi, H. Y, Musiwaro, P, Poterlowicz, K, Peng, Y, Scally, A. J, Patterson, L. H, Phillips, R. M, Sutton, C. W

“…Three dimensional multicell tumor spheroids (MCTS) provide an experimental model where the influence of microenvironmental conditions on protein expression can…”
Get full text

Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site by Vinader, Victoria, Haji-Abdullahi, Mohamed H, Patterson, L H, Afarinkia, Kamyar

“…A novel methodology is described for the efficient and divergent synthesis of pseudodisaccharides, molecules comprising of amino carbasugar analogues linked to…”
Get full text

AQ4N: a new approach to hypoxia-activated cancer chemotherapy by PATTERSON, L. H, MCKEOWN, S. R

“…Preclinical studies demonstrate that in vivo AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents with a dose-modifying factor of…”
Get full text

Tumour cytochrome P450 and drug activation by Patterson, L H, Murray, G I

“…The expression of drug metabolising cytochrome P450s (CYPs) notably 1A, 1B, 2C, 3A, 2D subfamily members have been identified in a wide range of human cancers…”
Get more information

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study by Steward, WP, Middleton, M, Benghiat, A, Loadman, PM, Hayward, C, Waller, S, Ford, S, Halbert, G, Patterson, LH, Talbot, D

“…Background: AQ4N (1,4-bis[[2-(dimethylamino)ethyl] amino]-5,8-dihydroxyanthracene-9, 10-dione bis-N-oxide dihydrochloride) is a prodrug which is selectively…”
Get full text

The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 by Potter, G A, Patterson, L H, Wanogho, E, Perry, P J, Butler, P C, Ijaz, T, Ruparelia, K C, Lamb, J H, Farmer, P B, Stanley, L A, Burke, M D

Get full text

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent by PATTERSON, L. H, MCKEOWN, S. R, RUPARELIA, K, DOUBLE, J. A, BIBBY, M. C, COLE, S, STRATFORD, I. J

“…AQ4 (1,4-Bis-[[2-(dimethylamino-N-oxide)ethyl]amino]5,8-dihydroxyanthrace ne-9, 10-dione) is a prodrug designed to be excluded from cell nuclei until…”
Get full text

Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach by Lane, C.S., Nisar, S., Griffiths, W.J., Fuller, B.J., Davidson, B.R., Hewes, J., Welham, K.J., Patterson, L.H.

“…We describe the direct identification of multiple cytochrome P450 (CYP) enzymes in healthy and cancerous tissue. CYPs in human liver colorectal metastases were…”
Get full text

What Do Coronary Artery Disease Patients Think about Their Treatments? An Assessment of Patients' Treatment Representations by Hirani, Shashivadan P., Patterson, David L.H., Newman, Stanton P.

“…This article investigates patients' beliefs about the intervention offered to manage their illness. Coronary artery disease (CAD) patients, 70 of whom were…”
Get full text

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N by Yakkundi, A, McErlane, V, Murray, M, McCarthy, H O, Ward, C, Hughes, C M, Patterson, L H, Hirst, D G, McKeown, S R, Robson, T

“…Drug metabolizing transgene products, which activate bioreductive cytotoxins, can be used to target treatment-resistant hypoxic tumors. The prodrug AQ4N is…”
Get full text

A PROTEOMIC APPROACH TO THE IDENTIFICATION OF CYTOCHROME P450 ISOFORMS IN MALE AND FEMALE RAT LIVER BY NANOSCALE LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION-TANDEM MASS SPECTROMETRY by NISAR, S, LANE, C. S, WILDERSPIN, A. F, WELHAM, K. J, GRIFFITHS, W. J, PATTERSON, L. H

“…Nanoscale reversed-phase liquid chromatography (LC) combined with electrospray ionization-tandem mass spectrometry (ESI-MS/MS) has been used as a method for…”
Get full text

Advanced microscopy solutions for monitoring the kinetics and dynamics of drug–DNA targeting in living cells by Errington, R.J., Ameer-beg, S.M., Vojnovic, B., Patterson, L.H., Zloh, M., Smith, P.J.

“…Many anticancer drugs require interaction with DNA or chromatin components of tumor cells to achieve therapeutic activity. Quantification and exploration of…”
Get full text

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N by GALLAGHER, R, HUGHES, C. M, MURRAY, M. M, FRIERY, O. P, PATTERSON, L. H, MCKEOWN, S. R, HIRST, D. G

“…AQ4N is a bioreductive drug that can significantly enhance the anti-tumour effect of radiation and cyclophosphamide. The aim of this study was to examine the…”
Get full text

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug by Raleigh, S M, Wanogho, E, Burke, M D, McKeown, S R, Patterson, L H

“…To establish the role of the human cytochromes P450 (CYPs) in the reductive metabolism of the novel anthraquinone di-N-oxide prodrug AQ4N. Metabolism of AQ4N…”
Get more information

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine by FRIERY, O. P, GALLAGHER, R, MURRAY, M. M, HUGHES, C. M, GALLIGAN, E. S, MCINTYRE, I. A, PATTERSON, L. H, HIRST, D. G, MCKEOWN, S. R

“…The ability of the bioreductive drugs AQ4N and tirapazamine to enhance the anti-tumour effect of cyclophosphamide was assessed in three murine tumour models…”
Get full text

A Preclinical Pharmacokinetic Study of the Bioreductive Drug AQ4N by LOADMAN, P. M, SWAINE, D. J, BIBBY, M. C, WELHAM, K. J, PATTERSON, L. H

“…AQ4N (1,4-bis-{[2-(dimethylamino- N -oxide)ethyl]amino}5,8-dihydroxyanthracene-9,10-dione) is in a class of bioreductive agents incorporating the aliphatic N…”
Get full text

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents : a new class of bioreductive agent by PATTERSON, L. H

“…NAD(P)H dependent cytochrome P450's and other haemoproteins under hypoxia, mediate two-electron reduction of a wide range of structurally dissimilar N-oxides…”
Get full text

A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry by Smith, Paul J, Wiltshire, Marie, Davies, Sharon, Patterson, Laurence H, Hoy, Terence

“…The deep red fluorescing agent (DRAQ5) is a synthetic anthraquinone with a high affinity for DNA and a high capacity to rapidly enter living cells or stain…”
Get full text

AQ4N : an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo by MCKEOWN, S. R, HEJMADI, M. V, MCINTYRE, I. A, MCALEER, J. J. A, PATTERSON, L. H

“…AQ4N (1,4-bis([2-(dimethylamino-N-oxide)ethyl]amino)5,8-dihydroxy- anthracene-9,10-dione) is a novel alkylaminoanthraquinone N-oxide which, on reduction, forms…”
Get full text